Creative Medical Technology (NASDAQ:CELZ) Shares Pass Below Fifty Day Moving Average of $3.35

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) shares crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $3.35 and traded as low as $2.98. Creative Medical Technology shares last traded at $2.98, with a volume of 10,558 shares trading hands.

Creative Medical Technology Stock Performance

The stock’s fifty day moving average is $3.33 and its two-hundred day moving average is $4.09. The firm has a market capitalization of $4.02 million, a price-to-earnings ratio of -0.80 and a beta of 2.11.

Creative Medical Technology (NASDAQ:CELZ) last posted its quarterly earnings results on Friday, August 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.27). The firm had revenue of $0.01 million for the quarter. Sell-side analysts anticipate that Creative Medical Technology Holdings, Inc. will post -3.29 earnings per share for the current year.

Hedge Funds Weigh In On Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Virtu Financial LLC acquired a new position in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 16,374 shares of the company’s stock, valued at approximately $85,000. Virtu Financial LLC owned about 1.21% of Creative Medical Technology at the end of the most recent quarter. Institutional investors own 1.42% of the company’s stock.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.